Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

Any body have any views on this share which has been trading sideways for a while? Prelims out on Tuesday.

It is due for a bounce.

bprg mangement will you please change that the name to biomakingabsolutleynoprogress!!! ta you have sorted this dispute out with seo and have gone backwards ever since.

Results due 12.4.2006.

Some good news before the results (usually means that results won't be so good!)

BioProgress launches oral strips for prevention of snoring

AFX



LONDON (AFX) - BioProgress PLC said it has launched a new oral anti-snoring product and oral caffeine strips aimed at boosting alertness.

The Ronflux strip, a dissolve-in-the-mouth product for the prevention of snoring, and the caffeine strips will first be available in France. The two products were launched this weekend at Pharmagora 2006, an annual French retail pharmacists' trade show.

The strips are made using BioProgress' SOLULEAVES technology, which allows active ingredients, colours and flavours to be incorporated into a non-genetically modified, non-animal derived film, which dissolves in the mouth.

newsdesk@afxnews.com

I don't have any problems in holding in this co long term.....I might be able to sleep a bit easier now!!
kim

For immediate release 12 April 2006

BioProgress plc: Preliminary Results for the year ended 31 December 2005

BioProgress plc (AIM: BPRG; NASDAQ: BPRG), the specialty pharmaceutical
company, today reports its Preliminary Results for the year ended 31 December
2005.

Highlights

* Turnover of 4.4 million, mostly generated in H2 2005, and gross profit of
1.8 million

* Cash balances of 6.5 million at year end

* Redemption of 5 million convertible bond for 1.65 million in cash and
1.65 million in shares

* Substantially removed the litigation risks within the business

* Restructuring of operations resulting in the reduction of both costs and
cash burn in the second half of the year by 3.4 million

* Successful restructuring of partnering arrangements to protect and
reinvigorate the company's commercialisation objectives

* Successful commercial launch of TABWRAP and WAFERTAB technologies

* First delivery of NROBE machine in cGMP facility

* Further investment in BioTec Films resulting in ability to supply cGMP
accredited film in February 2006

* New IP created in both the ingestible oral dosing and non-ingestible device
platforms

* Investment in infrastructure necessary to integrate the Dexo S.A acquisition
in 2006 moving the Group to pharmaceutical sales model

Commenting on the Results, Richard Trevillion, Chief Executive Officer of
BioProgress plc, said:

"Bioprogress is now a fully integrated specialty pharmaceutical company. 2005
was a year of two halves. It commenced with spiralling costs, worsening trading
conditions, partnership difficulties and operational confusion. However, as a
result of rapid action taken during the second half of the year by the new
management team, we have entered 2006 a very different company. All key
partnerships are progressing rapidly to full commercialisation and the Company
is also launching its own products with its own platforms.

The Company's first quarter 2006 trading has demonstrated the effectiveness of
the strategy implemented in the second half of the year. BioProgress is well
positioned to end the year for the first time in its history trading profitably
at an EBITDA level."

Application has been made to FTSE for BioProgress to be re-classified from
"Specialty Chemicals" to "Pharmaceuticals" within the Healthcare industry. It
is expected that this change will be announced in the summer.

About BioProgress plc:

BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the
company has over 80 patents granted or in application within 24 patent families
and has product development agreements and strategic alliances with several
global companies. As a virtually integrated business, BioProgress has acquired
sales and marketing resources within Europe and the US as a launch mechanism
for its own pharmaceutical products. The business continues to develop
innovative delivery mechanisms using its XGEL polymer technology, replacing
the need to use animal-derived gelatine in pharmaceutical and healthcare
products. For further information please go to
www.bioprogress.com

Introduction

BioProgress is pleased to report its Preliminary Results for the year ended 31
December 2005.

CHIEF EXECUTIVE'S REVIEW

The period under review was a pivotal year for BioProgress PLC (`BioProgress'
or "the Company") and its subsidiaries ("the Group"). 2005 commenced with
spiralling costs, worsening trading conditions, partnership difficulties and
operational confusion. However, as a result of rapid action taken during the
second half by the new management team we have entered 2006 a very different
company.

BioProgress is now a fully integrated specialty pharma and healthcare company.
We have exploited and will be further exploiting our novel technology platforms
for the benefit of the BioProgress group and its chosen partners and will be
investing in fast track development of all Group divisions. The technology
platforms will enable the group to rapidly differentiate its recently acquired
product lines through the newly formed Dexo group of companies and to formulate
its own unique oral dosage medicines. Furthermore, with our investment in an
international sales and marketing infrastructure, we will be able to distribute
the product range on an international basis. An example is the recent launch
this month at the Pharmagora Exhibition of the Ronflux anti-snoring range of
products and caffeine strips. The Ronflux range is one of Dexo SA's products,
reformulated in an enhanced oral dosage form. The reformulation and launch
utilized our formulation and production teams in the US and UK, and our sales
and marketing capability within the Dexo subsidiaries. The ability to create
and launch in such a short time frame since the acquisition was only completed
in January 2006, is testament to the hard work and capabilities of the whole
team. This sends a very powerful message to the market.

The restructuring implemented in the second half of 2005 has generated
operational as well as financial benefits to the group. Whilst development and
now formulation are fundamental drivers of value creation, they do so at a
fraction of their historical cost as the approach is now pre-market validated
development rather than research-led investment.

2005 performance review

There were two very distinct halves to the year and the performance of the
business has improved dramatically as the various restructuring and
repositioning plans have come to fruition.

First half year 2005

The first half of 2005 was dominated by the strategic and financial review.
This review was triggered when it was identified that previous trading
forecasts regarding BioTec Films LLC's revenues, in particular, were unlikely
to be achieved. It was also identified that costs were running at excessive
levels. Remedial action was taken to manage market expectation but also to reduce the
cost base and cash burn. These plans were successfully implemented.

Other changes were required of a more operational nature and were implemented
throughout the year as follows:

1. Review and restructuring of strategic partnering and licensing
arrangements.

The historical partnering arrangements were restructured where necessary
both to protect the Company and to reinforce and reinvigorate the
commercialisation objectives. Confidentiality undertakings govern the scope
of these arrangements but partner feedback has been, and continues to be
encouraging.

2. Operational controls.

Headcount was reduced significantly to the levels required to support the
strategic direction of the group with built-in flexibility for growth. As a
result of the implementation of financial control initiatives, costs are
now more tightly controlled with full operational accountability. This has
been made possible through the creation of fully transparent team and
project structures throughout the Group.

Operational management and reporting systems were installed to provide
consistency of approach, control of projects, transparency of resource
allocation and improved cost control.

Operational communication now works in a much more effective manner. Each
activity fulfils a part of the growth of the whole in an integrated
structure with frequent operational progress and control forums.

Operational Progress during the second half of 2005

An underlying asset of the business has always been the strength of its
intellectual property (`IP') and people. Notwithstanding the issues identified
earlier in the year and the required restructuring which took place, progress
of a positive nature has taken place throughout the year. In fact, the
restructuring accelerated the pace of some of the developments which are now
benefiting the Company.

New IP has been created strengthening our asset base in both the ingestible
oral dosing and non-ingestible device platforms.

The commercial launch of the TABWRAP and WAFERTAB technologies at the CPhI
exhibition in November was a great success and generated a number of
feasibility and evaluation enquiries, some of which have now turned into
commercial agreement discussions. In particular, progress with our TABWRAP
platform has enabled not only multiple partnership discussions but also allowed
the Group to rapidly add value to its own oral dose medicines giving them not
only enhanced properties but much improved marketing and pharmacological
profiles.

The first NROBE machine was delivered and installed in a cGMP facility in
June. Since then, significant progress has been made which has been positively
recognised by our partner FMC.

Investment has also been made in upgrading our BioTec Films LLC division. This
investment involved both process improvements as well as capital expenditure
throughout the second half of 2005. These improvements enabled the Company to
announce in February 2006 that we were able to supply cGMP accredited film both
externally to our partners and customers and as part of our investment in our
own products and our development into a specialty pharma and healthcare
business. Historically, BioTec could produce to food grade standard but this
was not sufficient approval to allow the Group to benefit from the higher
margin potential of the pharmaceutical industry.

Finally, on the financial side, in June 2005 we were able to redeem the
convertible bond issued in October 2004.

Post balance sheet events

By far the biggest change to the Group has been the acquisition of Dexo S.A.
and the creation of Dexo BioGenerics Limited which, although completed in early
January, had been the focus of the Company's energies in the weeks leading up
to the year end. Dexo was a long-standing profitable private company with
specific expertise in registering and marketing innovative branded products
into the French healthcare system. It operates in the area of registered
pharmaceuticals, and specialises in medicines to treat gastrointestinal
illness, and products for ear, nose and throat ailments, along with a treatment
for Wilson's Disease. Dexo SA continues to be managed by Mr. Jean-Francois
Sfarti, the former CEO of Sanofi Pharma France. In addition, as part of both
the preparation for and rapid expansion of Dexo, the Company has recruited
senior pharmaceutical management personnel.

Through the creation of the new pharmaceutical division, BioProgress will be
able to apply its own technologies to its own products and develop improved
formulations, thus improving traditional medicines and reinvigorating brands.
We have already started to do this ahead of the predicted timetable, not only
creating a profitable revenue stream for the Group but demonstrating to
consumers and partners the benefits of our technologies.

In addition, on 27 January 2006 the company settled the litigation with
Stanelco Plc, whereby BioProgress Technology Limited and Stanelco RF
Technologies Limited were disputing entitlement to three families of patents
relating to the making of water-soluble capsules sealed using radio frequency.
Under the main terms of settlement, both parties will be able to commercially
exploit all three patent families.

Financial review

Turnover was 4.4 million for the year ended 31 December 2005, an increase of
77% over 2004. Most of this revenue came from BioTec Films Inc which was
acquired by the group in March 2004. Adjusting 2004, as there was only 9 months
of revenue reported post acquisition, turnover increased by 32% in 2005.

This revenue increase was also delivered with an improved gross margin. The
gross margin in 2004 was 32% and this increased in 2005 to 40%. The improvement
in turnover was a result of rapid management action earlier in the year
yielding new clients with a reduced cost base.

Administrative expenses for the full year were 11.26 million compared to 8.4
million. The interim announcement made in September 2005 identified substantial
increases in operating costs when compared to 2004 and remedial action taken by
the new management team during the second half of the year. The reported
administrative expenses for the first 6 months were 7.3 million and this was
successfully reduced to 3.9 million for the second half of the year. Further
reductions in non strategic costs have been implemented with the expectation
that the resultant overhead structure will be more representative of the
current underlying business.

The loss for the year ended 31 December 2005 was 8.7 million compared to 7.1
million in 2004. The majority of the 2005 losses were incurred in the first
half of the year. This clearly illustrates the impact of the internal
restructuring and extensive cost reduction program implemented during the
second half of the year. The loss per ordinary share was 7.2 p (2004: loss
6.3p).

Cash on the balance sheet was 6.5 million at the year end (2004: 14.4
million). The cash has been used, primarily to fund the operations but 1.65
million was used to part settle the convertible debt. Improvements have been
made in the management of working capital during the year with reductions in
both stock and debtor balances positively contributing to the cash flow from
operating activities.

In June 2005, the Company redeemed the 5 million convertible debt via the
issue of 1.65 million of ordinary shares and 1.65 million in cash. In
accordance with the accounting standard (FRS 25), 544,000 has been recognised
as the accounting gain in the profit and loss account within net interest.

Outlook

In 2006 we intend to capitalise upon the momentum built in the second half of
2005. The Company is already enjoying strong organic growth in all business
areas and the outlook for the remainder of this year is [extremely] positive.

Richard Trevillion: Chief Executive Officer


A positive turnaround for one year under the new management with a promising outlook for more to come. We will just have to wait and see!

My confidence in this company remains, they should have a clear run to good profits from here on.
kim

kim
I agree not in but watching.

Hi. Just paid for moneyam L2 and decided to have a look at the threads. i wondered who was here (normally use another bb).

imo results good and the broker note is ultra conservative. very positive of a strong newsflow from here.

hambi

Is this end of BPRG (another Skyepharma) they seem to have given the market absolutely nothing and im watching my investment get smaller and smaller. Please change your name to Bio-goingbackwardsfasterthanJesonButton. how do these management people sleep at night??

Kivver, both BPRG and SEO are both under-achievers.

at least theres a chink of light with seo!!

If youve had a good day please consider giving a donation to the lads dressed as Elvis racing 350 miles to the North Pole on behalf of Great Ormond Street Hospital It makes the London Marathon seem like a stroll in the park!
To donate or view how theyre getting on visit
http://www.elvispolarchallenge.co.uk/
thanks for your time

Remember these, Maybe they are doing the right things.

For immediate release
25 April 2006

BioProgress signs sales and marketing partner for France

Cambridge, UK, 25 April 2006 - BioProgress (AIM: BPRG; NASDAQ: BPRG), the
specialty pharma and healthcare company, has signed a strategic partnership
agreement with the pharmaceutical sales and marketing company, Cristers, for
the promotion and distribution of its over-the-counter (OTC) SOLULEAVES
products in France.

The products that Cristers will market for BioProgress' subsidiary, Dexo S.A.
(Dexo) include the newly-launched Ronflux anti-snoring film strips, a range of
vitamin, mineral, nutritional and herbal products and a licensed range of
pharmaceutical OTC medicines. Each of these products uses BioProgress'
SOLULEAVES technology, in which active ingredients, colours and flavours are
incorporated into a GMO-free, non-animal derived film, which dissolves in the
mouth, releasing the active ingredients.

With over 160 sales personnel based in Herblay, near Paris, France, and
telemarketing and distribution systems in place, Cristers is well positioned to
sell Dexo products in France. The Company was formed in 2005 by Stephane Joly,
President of Cristers, with the backing of Investinov and Nepenthes. Investinov
is France's leading contract sales organisation with over 1200 medical
representatives. Nepenthes is one of France's largest retail pharmacist buying
groups with over 22% of the market share.

Richard Trevillion, CEO of BioProgress said: "This is an important strategic
partnership for BioProgress. Cristers has excellent credentials and will
provide Dexo with significant resources in the areas of pharmacy promotion,
direct marketing and promotion to doctors. With the backing of France's largest
contract sales organisation, and the largest pharmacist buying group, Cristers
will be able to rapidly expand the Dexo sales coverage in France. Our
confidence in the Cristers management team, has led us to commit to a long-term
strategic partnership."

BioProgress launched two of its SOLULEAVES products, Ronflux strips and
caffeine strips, via Dexo at Pharmagora 2006, an annual French retail
pharmacists' trade show, earlier this month. Due to the positive response to
these products at the show, BioProgress has accelerated its development and
launch programmes for all its SOLULEAVES products, to meet the anticipated
demand. These products are manufactured at the BioProgress group's cGMP
accredited facility based in Tampa, Florida, USA.

Short on FD resignation.

Perhaps things are beginnning to look up.

"BioProgress plc announces strategic joint development agreement with Uluru Inc.

Cambridge, UK, 4 May 2006 BioProgress plc (AIM: BPRG; NASDAQ: BPRG), the
speciality pharma and healthcare company, today announced that it has signed a
joint strategic development agreement with the emerging speciality
pharmaceutical company, Uluru Inc. The companies will initially work together
to develop an anti-emetic product for the relief of nausea, using a combination
of BioProgress' film technology and Uluru's Oradisc drug delivery technology.
This relationship will then go on to develop further therapeutic products.

Uluru Inc. is focused on the development of a portfolio of wound management,
plastic surgery and oral care products to provide patients and consumers
improved clinical outcomes through controlled delivery. Uluru's OraDisc
technology is an innovative erodible film technology that sticks to mucous
membranes and allows sustained release of actives into the systemic
circulation over a period of several hours.

The new products are expected to resemble BioProgress' in-the-mouth range of
films strips, which can dissolve instantly, releasing the embedded active
ingredients. However, by adding the Oradisc technology to these films, the
resulting products will not only be fast acting, but will also offer sustained
release of actives over several hours. These new products will therefore have
properties that neither technology could achieve on its own.

Patients with nausea are often unable to take tablets effectively, so an
in-the-mouth instant release anti-emetic offers a good solution to treat acute
nausea and the OraDisc technology provides a longer term solution to the
problem. This is a therapeutic area with a large unmet need. BioProgress has a
large amount of in-house expertise in this area and Uluru has significant
experience in development of film technology through FDA approval.

Richard Trevillion, CEO of BioProgress, said: "We are delighted to be entering
a strategic partnership with Uluru Inc. The technologies from both companies
are complimentary and can work in combination to create products with both
instant release and sustained release characteristics. This approach has the
potential to create real therapeutic value and enhance the effectiveness of
medicines."

Kerry Gray, CEO of Uluru Inc. said: "This partnership is exciting for both
companies as we can access the development strengths and resources of both
groups. Our ability to combine instant release with sustained delivery over an
extended period has the potential to create considerable value. We will be
applying proven technologies to existing medicines with the objective of
dramatically improving the resultant profile."

+ + +

About BioProgress plc:
BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the
company has over 80 patents granted or in application within 24 patent families
and has product development agreements and strategic alliances with several
global companies. As a virtually integrated business, BioProgress has acquired
sales and marketing resources within Europe and the US as a launch mechanism
for its own pharmaceutical products. The business continues to develop
innovative delivery mechanisms using its XGEL polymer technology, replacing
the need to use animal-derived gelatine in pharmaceutical and healthcare
products. For further information please go to
www.bioprogress.com


About Uluru Inc.:
Uluru Inc. is an emerging speciality pharmaceutical company focused on the
development of a portfolio of wound management plastic surgery and oral care
products to provide patients and consumers improved clinical outcomes through
controlled delivery utilizing its innovative transmucosal delivery system and
Hydrogel Nanoparticle aggregate technology.

This press release contains certain statements that are forward-looking within
the meaning of Section 27a of the Securities Act of 1933, as amended, and that
involve risks, and uncertainties, including but not limited to statements made
relating to the establishment of a sales and marketing organization, the
marketing of three additional products and the achievement of a listing on
NASDAQ or an exchange. These statements are subject to numerous risks,
including but not limited to the risks detailed in the Company's Annual Report
on Form 10-K, for the year ended December 31, 2004, Quarterly Report on Form
10-Q for the quarter ended September 30, 2005 and other reports filed by us
with the Securities and Exchange Commission

For further information please contact:

BioProgress plc +44 (0) 1223 394250
Richard Trevillion, Chief Executive Officer

Northbank Communications +44 (0) 207 886 8150
Sue Charles
Gemma Bradley
Justine Lamond

A statement designed to stem the continuing fall in Bioprogress' share price failed to make an impact. The speciality pharmaceutical and healthcare company said that it remained confident of its prospects, confirming its expectation of further positive newsflow in the near term. The group put the recent decline in its share price down to the volatility in the wider market. However, the company has never attracted a significant degree of stability in its share price, so the recent swings are probably just as much company related Bioprogress related. Its shares finished the session 2p easier at 41p.

KD.

doe's anyone hold any rgt. good news today. buys are up.

Richard Trevellion is in the States this week, investors are expecting good news and a rising sp.

RT
18th May

The directors remain extremely confident in the prospects of the group and
anticipate further positive newsflow resulting from the continued
implementation of the Company's strategy, in the near term.

It's in the bag.

Be quick!

"The Company is already enjoying strong organic growth in all business areas and the
outlook for the remainder of this year is [ extremely] positive." (RT 12/04/2006) >

don't get bpgged down by the past. The last six months have seen massive restructuring. stable sp and great prospects